Canada markets open in 2 hours 10 minutes

Supernus Pharmaceuticals, Inc. (S49.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
25.60-0.60 (-2.29%)
As of 08:02AM CEST. Market open.
Currency in EUR

Valuation Measures4

Market Cap (intraday) 1.42B
Enterprise Value 1.18B
Trailing P/E 65.58
Forward P/E 20.45
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)2.60
Price/Book (mrq)1.68
Enterprise Value/Revenue 2.15
Enterprise Value/EBITDA 16.10

Trading Information

Stock Price History

Beta (5Y Monthly) 1.01
52-Week Change 3-15.29%
S&P500 52-Week Change 329.31%
52 Week High 332.80
52 Week Low 321.40
50-Day Moving Average 329.00
200-Day Moving Average 326.66

Share Statistics

Avg Vol (3 month) 3N/A
Avg Vol (10 day) 3N/A
Shares Outstanding 554.97M
Implied Shares Outstanding 655.34M
Float 849.05M
% Held by Insiders 15.02%
% Held by Institutions 1106.70%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Mar 31, 2024

Profitability

Profit Margin -2.60%
Operating Margin (ttm)-2.96%

Management Effectiveness

Return on Assets (ttm)0.23%
Return on Equity (ttm)-1.68%

Income Statement

Revenue (ttm)597.4M
Revenue Per Share (ttm)10.93
Quarterly Revenue Growth (yoy)-6.60%
Gross Profit (ttm)N/A
EBITDA 90.63M
Net Income Avi to Common (ttm)-15.51M
Diluted EPS (ttm)-0.26
Quarterly Earnings Growth (yoy)-99.30%

Balance Sheet

Total Cash (mrq)297.74M
Total Cash Per Share (mrq)5.42
Total Debt (mrq)42.13M
Total Debt/Equity (mrq)4.53%
Current Ratio (mrq)1.73
Book Value Per Share (mrq)16.91

Cash Flow Statement

Operating Cash Flow (ttm)100.36M
Levered Free Cash Flow (ttm)588.32M